|
|
|
ISIS - Isis Pharmaceuticals, Inc.
Isis
Pharmaceuticals, Inc. was a biopharmaceutical company that was focused
on discovering and developing RNA-based therapeutics. The company was
founded in 1989 and was based in Carlsbad, California.
Isis
Pharmaceuticals had a unique approach to drug discovery and
development that involved targeting specific messenger RNA (mRNA)
sequences that are involved in disease processes. By inhibiting the
production of disease-causing proteins, the company's drugs had the
potential to treat a wide range of diseases.
The company had a
number of drug candidates in various stages of development for
diseases such as cancer, cardiovascular disease, and rare genetic
disorders. One of its most promising drug candidates was Kynamro,
which was approved by the FDA in 2013 for the treatment of homozygous
familial hypercholesterolemia.
In 2015, Isis Pharmaceuticals
changed its name to Ionis Pharmaceuticals, Inc. to better reflect its
focus on developing drugs that target RNA. The company continues to be
a leader in the field of RNA-targeted therapeutics and has a number of
promising drugs in it
|
|
|
|
|
